Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

GREY:COTQF - Post by User

Cotinga Pharmaceuticals Inc

Bullboard Posts

Post by beatsworkingon Oct 17, 2000 1:18pm

151 Views

Post# 2666638

Basher only bash good stocks.

Thanks folks for getting the message out. This saves the COT management team big bucks for all us longs and lets them buy more pieces of the puzzle. Thanks again you dudes are going a great job. Regards Beats

Bullboard Posts

BMO evolves InvestorLine with enhanced tools for options trading